No single ticker was named. Healthcare ETFs are one way for retail investors to get exposure. Not a recommendation.
Small-cap biotech M&A surge driven by patent cliffs
Small-cap biotech companies are framed as prime targets for an impending surge in M&A as major pharmaceutical firms seek to replace revenue lost to expiring patents.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.